-
Mashup Score: 1Petros Grivas, MD, PhD - 2 day(s) ago
Dr. Grivas is the clinical director of University of Washington (UW) Medicine Genitourinary Cancers Program and Professor in the Division of Hematology Oncology, Dept. of Medicine, UW and in the
Source: society.asco.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval - PMLiVE - 2 month(s) ago
About 614,000 people are diagnosed with bladder cancer globally every year
Source: pmlive.comCategories: General Medicine News, Oncologists1Tweet-
https://t.co/AtbZAL06a9
-
-
Mashup Score: 34
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet-
Nice @JCO_ASCO editorial on #PARPi combinations in 1st line #mCRPC #prostatecancer, but let's address some barriers: 1. Real-world access to #BRCA & #HRR testing needs improvement for #PARPi use 2. Regardless of #HRR status, we've shown pooled OS benefit https://t.co/fKjqk1qTNR https://t.co/FcsUAjFJDr
-
-
Mashup Score: 3Giuseppe Banna: How ADCs are revolutionizing patient outcomes in real-time - OncoDaily - 2 month(s) ago
Giuseppe Banna: How ADCs are revolutionizing patient outcomes in real-time / ADCs, Alessandra Curioni Fontecedro, Antibody drug conjugates, cancer, cancer
Source: oncodaily.comCategories: General Medicine News, Oncologists1Tweet-
RT @oncodaily: How ADCs are revolutionizing patient outcomes in real-time - @gbanna74 @PTarantinoMD https://t.co/bHS2mddVyk #ADCs #Canc…
-
-
Mashup Score: 31
PURPOSE Paclitaxel, ifosfamide, and cisplatin (TIP) is an established salvage regimen for germ cell tumors (GCT) on the basis of a phase II trial, but efficacy on a large patient cohort including patients with unfavorable risk features and long-term outcomes has not been reported. Herein, we report updated treatment efficacy and long-term follow-up with TIP. PATIENTS AND METHODS Patients with GCT who received TIP after cisplatin-based chemotherapy were eligible. Favorable response (complete response or partial response with negative tumor markers), overall survival (OS) and progression-free survival (PFS) rates, relapse, and toxicity were determined. Disease was reclassified according to the International Prognostic Factor Study Group (IPFSG) score. RESULTS Of the 104 patients, 87 had favorable risk factors and 17 had at least one unfavorable factor by Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Ten patients were treated for a second gonadal primary GCT. With a median foll
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Paclitaxel, Ifosfamide, & Cisplatin (TIP) show long-term efficacy as salvage chemotherapy for germ cell tumors— similar outcomes for favorable/unfavorable risk diseases. Eagerly awaiting the TIGER trial results! @JCO_ASCO #OncologyResearch #GermCellTumors https://t.co/sDKaupV2ul
-
-
Mashup Score: 1
Giuseppe Banna: 177Lu-PSMA-617 for metastatic prostate cancer in LMICs / Akash Maniam, Amit Ghose, Aruni Ghose, cancer, Giuseppe Banna, Giuseppe L. Banna,
Source: oncodaily.comCategories: General Medicine News, Oncologists1Tweet-
RT @oncodaily: 177Lu-PSMA-617 for metastatic prostate cancer in LMICs - @gbanna74 https://t.co/eIGIueekAu #Cancer #ProstateCancer #OncoD…
-
-
Mashup Score: 2Giuseppe Banna: Promising results for Telisotuzumab Vedotin in advanced NSCLC - OncoDaily - 3 month(s) ago
Giuseppe Banna: Promising results for Telisotuzumab Vedotin in advanced NSCLC / Aaron S. Mansfield, Alona Zer, c-Met protein, cancer, Chih-Hsi Kuo, Christina
Source: oncodaily.comCategories: General Medicine News, Oncologists1Tweet-
RT @oncodaily: Promising results for Telisotuzumab Vedotin in advanced NSCLC - @gbanna74 (@PHU_NHS) https://t.co/kpZDFu5wz3 #NSCLC #Telis…
-
-
Mashup Score: 14Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer | JCO Precision Oncology - 4 month(s) ago
PURPOSE Next-generation sequencing (NGS) has enabled the detection of concomitant driver alterations in non–small cell lung cancer (NSCLC). However, the magnitude and clinical relevance of concomitant drivers remain to be explored. METHODS We profiled concomitant driver alterations of EGFR+ NSCLC by using targeted NGS. The associated genomic and clinical features were analyzed and validated in an independent The Cancer Genome Atlas cohort of patients with EGFR+ NSCLC. RESULTS Out of the total patient population, 334 patients had EGFR mutations along with concomitant driver mutations, comprising 3.09% of the entire cohort. The most frequent co-occurring mutations with sensitizing EGFR mutations include KRAS at 53.9%, followed by ERBB2 at 24.3%, MET at 16.5%, and BRAF at 3.3%. KRAS mutations in concomitant drivers were frequently hyperexchange mutations (25.6% v 8.2%, P < .001), compared with KRAS single drivers. EGFR/ERBB2 drivers exhibited a higher incidence of ERBB2 amplification (40.
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Frequent co-occurring driver mutations in classical EGFR-mutated NSCLC, including KRAS, ERBB2, and MET. Concomitant mutations impact prognosis and could guide personalized therapy. #LungCancer #EGFR #PrecisionMedicine https://t.co/RsDTRyzUC1)https://t.co/TggfmXs1ej
-
-
Mashup Score: 0Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic Screening | JCO Precision Oncology - 4 month(s) ago
PURPOSE Genetic susceptibility to nonsyndromic renal cell carcinoma (RCC) remains poorly understood, especially for different histological subtypes, as does variations in genetic predisposition in different populations. The objectives of this study were to identify risk genes for RCC in the Canadian population, investigate their clinical significance, and evaluate variations in germline pathogenic variants (PVs) among patients with RCC across the globe. MATERIALS AND METHODS We conducted targeted sequencing of 19 RCC-related and 27 cancer predisposition genes for 960 patients with RCC from Canada and identified genes enriched in rare germline PVs in RCC compared with cancer-free controls. We combined our results with those reported for patients from Japan, the United Kingdom, and the United States to investigate PV variations in different populations. Furthermore, we evaluated the performance of referral criteria for genetic screening for including patients with rare PVs. RESULTS We id
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
#CancerResearch #Genetics #RCC https://t.co/GbQs2OVh1w
-
-
Mashup Score: 8
This cohort study compares the use of immune checkpoint inhibitor therapy with conventional chemotherapy in patients with non–small cell lung cancer (NSCLC) and overweight or obesity.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet-
Challenging the #obesity paradox in #NSCLC #immunotherapy. Surprised by better HR with immunotherapy in cachexia. Can this Japanese population evidence be generalizable? 🤔 @ACortelliniMD https://t.co/ISJ7qpWJy3 https://t.co/uPVtXcsQAE
-
Just a reminder and correction: @PGrivasMDPhD is a candidate for the Nominating committee (https://t.co/0Ax3kmamLj) but for the ASCO Board of Directors you can vote @n8pennell (https://t.co/mF0fBINikC)